SCHEMBL8166587

SCHEMBL8166587

CCOC(=O)Cc1cn(Cc2cccc(O)c2)c2ccccc12

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 2/20 0.60
CHRNA7 P36544 2/20 0.60
CHRNA4 P43681 2/20 0.60
LMNA P02545 4/20 0.55
ALDH1A1 P00352 3/20 0.55
L3MBTL1 Q9Y468 1/20 0.51
PLA2G2A P14555 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.49
NPSR1 Q6W5P4 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
F2RL3 Q96RI0 1/20 0.47
FNTA P49354 2/20 0.46
FNTB P49356 2/20 0.46
CREBBP Q92793 1/20 0.46
ICMT O60725 2/20 0.46
HTT P42858 1/20 0.45
ALOX5 P09917 1/20 0.45
P2RX7 Q99572 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8187802 0.88 FNTA (0.59) CHRNB2CHRNA7CHRNA4LMNAALDH1A1
SCHEMBL8181059 0.87 CHRNB2 (0.58) CHRNB2CHRNA7CHRNA4LMNAALDH1A1
SCHEMBL8173457 0.87 PLA2G2A (0.55) LMNAALDH1A1L3MBTL1PLA2G2ASMN1; SMN2
SCHEMBL13931024 0.86 LMNA (0.54) LMNAALDH1A1L3MBTL1PLA2G2ASMN1; SMN2
SCHEMBL13931030 0.85 LMNA (0.53) CHRNB2CHRNA7CHRNA4LMNAALDH1A1
SCHEMBL13931031 0.85 LMNA (0.53) CHRNB2CHRNA7CHRNA4LMNAALDH1A1
SCHEMBL8175090 0.82 FNTA (0.57) LMNAALDH1A1L3MBTL1F2RL3FNTA
SCHEMBL13931028 0.82 PPARG (0.56) LMNAALDH1A1L3MBTL1PLA2G2ANPSR1
SCHEMBL13931034 0.81 ALDH1A1 (0.50) LMNAALDH1A1L3MBTL1F2RL3FNTA
SCHEMBL8174682 0.80 LMNA (0.51) LMNAALDH1A1L3MBTL1PLA2G2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-02-19 US disclosed
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-02-19 US disclosed
WO-2008100867-A2 NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2008-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION EIF2AK2, HAVCR2, HCCS CHRNB2 4827/4885CHRNA7 4835/4885CHRNA4 4872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.